Individualized Chemotherapy
Phase 2Small molecule
Individualized Chemotherapy is one of 98 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 2.
3
Indications
5
Total Trials
4
Active Trials
97
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
307 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Individualized Chemotherapy
ZZhejiang University
Phase 2
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Secretin-Ferring
FerringPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Pancreatic Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Individualized Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang University